Department of Cardiology, Peking University People's Hospital, Beijing, China.
Int J Clin Pract. 2020 Dec;74(12):e13628. doi: 10.1111/ijcp.13628. Epub 2020 Sep 3.
Hypertensive patients with a blunted or absent nocturnal blood pressure (BP) drop (non-dipper) are associated with arterial stiffening and additional cardiovascular risk. Non-dipper hypertension is prevalent in young and middle-aged adults; but the optimal antihypertensive strategy remains unclear. There is a need to explore the effects of different antihypertensive agents and time of administration on recovery of dipper rhythm and arterial stiffness in this population.
NARRAS is a randomised controlled trial (RCT), designed to evaluate the effects of long-acting antihypertensive agents administrated in daytime or at nighttime on BP rhythm restoration and arterial stiffness in young and middle-aged non-dipper hypertensive patients. Participants will be randomly assigned to nifedipine GITS (gastrointestinal therapeutic system) 30 mg or amlodipine besylate 5 mg once daily, either taken in the morning or at night. Subjects will be divided into the following groups: group A. nifedipine administrated in the morning (N-M); B. nifedipine at night (N-N); C. amlodipine in the morning (A-M); D. amlodipine at night (A-N). If BP is not at goal during 4 week's visit, dosage of antihypertensive agents will be doubled. BP is measured via 24-hour ambulatory BP monitoring (ABPM) and arterial stiffness is examined before and after 8 weeks of pharmaceutical intervention. The primary endpoint is the difference of average nighttime systolic BP reduction between nifedipine GITS and amlodipine. The second endpoint is the percentage of restoration of a dipper rhythm at 8 weeks. The potential of nighttime dosing on arterial stiffness is also investigated. A sample size of 120 will have 80% power to detect a 3 mm Hg nighttime systolic BP difference between 2 drugs determined with ABPM.
NARRAS study is the first RCT to evaluate the effects of nifedipine GITS and amlodipine besylate on restoration of dipping rhythm and arterial elasticity, either administrated in the morning or evening, in younger non-dipper hypertensive subjects. The findings of NARRAS are likely to be potential to facilitate new therapeutic strategies for this condition.
NARRAS was registered in clinicaltrials.gov, NCT02940548.
夜间血压(BP)下降减弱或消失的高血压患者(非杓型)与动脉僵硬和额外的心血管风险有关。非杓型高血压在年轻和中年人群中较为常见;但最佳的降压策略仍不清楚。需要探讨不同降压药物和给药时间对该人群恢复杓型节律和动脉僵硬的影响。
NARRAS 是一项随机对照试验(RCT),旨在评估白天或夜间给予长效降压药物对年轻和中年非杓型高血压患者血压节律恢复和动脉僵硬的影响。参与者将被随机分配至硝苯地平控释片(GITS)30mg 或苯磺酸氨氯地平 5mg,每日一次,分别在早上或晚上服用。受试者将分为以下几组:A 组. 硝苯地平早上服用(N-M);B. 硝苯地平晚上服用(N-N);C. 氨氯地平早上服用(A-M);D. 氨氯地平晚上服用(A-N)。如果 4 周就诊时血压未达标,将加倍降压药物剂量。通过 24 小时动态血压监测(ABPM)测量血压,在药物干预 8 周前后检查动脉僵硬。主要终点是硝苯地平 GITS 和氨氯地平之间夜间收缩压平均降低的差异。次要终点是 8 周时恢复杓型节律的百分比。还研究了夜间给药对动脉僵硬的影响。120 名样本量将有 80%的效力检测到 ABPM 确定的两种药物之间夜间收缩压差异 3mmHg。
NARRAS 研究是第一项评估硝苯地平 GITS 和苯磺酸氨氯地平在年轻非杓型高血压患者中恢复杓型节律和动脉弹性的 RCT,无论是在早上还是晚上给药。NARRAS 的研究结果可能为该疾病提供新的治疗策略。
NARRAS 在 clinicaltrials.gov 上注册,NCT02940548。